• General multiple sclerosis (MS)
  • MS - Dimethyl fumarate
  • MS - Natalizumab
  • MS - Peginterferon beta-1a
    • The areas of research currently being considered to support studies related to peginterferon beta-1a in multiple sclerosis can be found below.

      In scope:  

      1. Real-world effectiveness as assessed by quality of life, cognition, adherence and treatment satisfaction vs other platform therapies, especially other injectables
      2. Examinations of work productivity, pharmacoeconomics, and health resource utilization
      3. Assessment of novel ways to mitigate injection site reactions (ISR) and flu-like symptoms (FLS) or better manage patients who experience these adverse events
         

      Out of scope:

      1. Biomarker studies trying to identify specific responder populations among patients treated with pegylated interferon-beta 1a
      2. Studies on its MoA
         

      Of note: Study designs for research objectives that have been well-researched in the past need to be powered to derive statistically meaningful conclusions and provide new scientific observations.

      Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee that support will be awarded.

  • MS - Prolonged-release fampridine